Vaccines and Related Biological Products Advisory Committee

Vaccines and Related Biological Products Advisory Committee. It is a critical advisory panel to the Center for Biologics Evaluation and Research within the Food and Drug Administration. The committee provides independent expert advice on the safety, effectiveness, and appropriate use of vaccines, allergenic products, and other biological therapeutics. Its recommendations are pivotal in the regulatory review process for new product approvals and for existing products on the U.S. market.

Purpose and function

The primary purpose is to review and evaluate data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products. This function directly supports the regulatory mission of the Food and Drug Administration and its Center for Biologics Evaluation and Research. The committee advises on the licensure of new products, such as those for influenza, COVID-19, and human papillomavirus, and considers post-marketing safety issues. It also provides guidance on complex regulatory and scientific questions pertaining to blood products, allergenics, and tissue-based therapies.

Membership and structure

Membership consists of a core of voting members selected by the Commissioner of Food and Drugs for their expertise in fields like immunology, molecular biology, infectious diseases, and biostatistics. The roster typically includes experts from institutions like the National Institutes of Health, Johns Hopkins University, and the Mayo Clinic. The structure includes a designated chair and may include non-voting industry and consumer representatives. All members are subject to stringent federal conflict of interest regulations to ensure impartiality in their deliberations.

Meetings and activities

Meetings are publicly announced in the Federal Register and are often held at FDA White Oak Campus in Silver Spring, Maryland. Key activities involve reviewing Biologics License Application dossiers, Emergency Use Authorization requests, and post-marketing safety data from systems like the Vaccine Adverse Event Reporting System. Notable meetings have focused on vaccines for SARS-CoV-2, respiratory syncytial virus, and annual strain selection for the influenza vaccine. Proceedings are webcast, and transcripts are made available to the public.

Regulatory impact and decisions

The committee's recommendations, while not legally binding, carry immense weight in the final regulatory decisions made by the Food and Drug Administration. Its endorsements have been central to the approvals of pivotal vaccines, including those for poliovirus, Haemophilus influenzae type b, and meningococcal disease. Conversely, its deliberations have led to revised labeling, restricted use, or market withdrawal of products, as seen in historical cases involving rotavirus vaccine and certain influenza formulations. The advice directly influences public health policy set by agencies like the Centers for Disease Control and Prevention.

History and evolution

The committee was formally established in 1964 under the Public Health Service Act to advise the Division of Biologics Standards, a predecessor to today's Center for Biologics Evaluation and Research. Its role expanded significantly following the National Childhood Vaccine Injury Act of 1986 and during public health emergencies like the HIV/AIDS epidemic and the 2009 swine flu pandemic. The evolution of its mandate reflects advances in biotechnology, such as the review of recombinant DNA and mRNA vaccine platforms. Its proceedings during the COVID-19 pandemic, particularly regarding vaccines from Pfizer and Moderna, underscored its enduring role in the national public health infrastructure.

Category:Food and Drug Administration Category:Medical and health organizations based in the United States Category:Advisory committees in the United States